Glitazone prescribers heed safety warnings

Australian endocrinologists appear to have heeded safety concerns for thiazolidinediones and reduced prescribing even before warnings were made by our own regulator, a new study shows.

Prescribing of rosiglitazone for type 2 diabetes peaked in 2007 and then went into decline immediately after a landmark study that suggested cardiovascular safety concerns, according to an analysis of PBS data by Queensland researchers.